{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Insulin+glargine+U100", "query": { "intervention": "Insulin glargine U100" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 24, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Insulin+glargine+U100&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-26T07:03:45.069Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04537923", "title": "A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Tirzepatide", "type": "DRUG" }, { "name": "Insulin Lispro (U100)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1428, "start_date": "2020-10-19", "completion_date": "2022-11-01", "has_results": true, "last_update_posted_date": "2023-11-02", "last_synced_at": "2026-09-26T07:03:45.069Z", "location_count": 40, "location_summary": "Sheffield, Alabama • Fresno, California • Huntington Park, California + 36 more", "locations": [ { "city": "Sheffield", "state": "Alabama" }, { "city": "Fresno", "state": "California" }, { "city": "Huntington Park", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04537923" }, { "nct_id": "NCT06340854", "title": "A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes, Type 2" ], "interventions": [ { "name": "Insulin icodec", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 412, "start_date": "2024-04-19", "completion_date": "2025-06-13", "has_results": true, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-09-26T07:03:45.069Z", "location_count": 27, "location_summary": "Fresno, California • Hawthorne, California • La Jolla, California + 23 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Hawthorne", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Lincoln", "state": "California" }, { "city": "Fleming Island", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06340854" }, { "nct_id": "NCT02058160", "title": "Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Insulin glargine/lixisenatide (HOE901/AVE0010)", "type": "DRUG" }, { "name": "Insulin glargine (HOE901)", "type": "DRUG" }, { "name": "Metformin (Background Drug)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 736, "start_date": "2014-01", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2017-05-09", "last_synced_at": "2026-09-26T07:03:45.069Z", "location_count": 108, "location_summary": "Birmingham, Alabama • Sun City, Arizona • Tempe, Arizona + 91 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02058160" }, { "nct_id": "NCT03013985", "title": "Glargine U300 Hospital Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Glargine U300", "type": "DRUG" }, { "name": "Glargine U100", "type": "DRUG" }, { "name": "Glulisine Insulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 247, "start_date": "2017-05-17", "completion_date": "2019-03-22", "has_results": true, "last_update_posted_date": "2020-05-07", "last_synced_at": "2026-09-26T07:03:45.069Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Minneapolis, Minnesota • Cleveland, Ohio", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03013985" }, { "nct_id": "NCT03336528", "title": "Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Degludec", "type": "DRUG" }, { "name": "Glargine", "type": "DRUG" }, { "name": "Aspart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2018-01-02", "completion_date": "2021-03-01", "has_results": true, "last_update_posted_date": "2022-03-31", "last_synced_at": "2026-09-26T07:03:45.069Z", "location_count": 4, "location_summary": "Atlanta, Georgia • New York, New York • Spokane, Washington", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "New York", "state": "New York" }, { "city": "Spokane", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03336528" }, { "nct_id": "NCT03668808", "title": "Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "Insulin Degludec", "type": "DRUG" }, { "name": "Insulin Glargine", "type": "DRUG" }, { "name": "TRESIBA® FLEXTOUCH®", "type": "DEVICE" }, { "name": "LANTUS® SOLOSTAR® INSULIN PEN", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sansum Diabetes Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 25, "start_date": "2018-11-16", "completion_date": "2020-09-19", "has_results": true, "last_update_posted_date": "2022-11-01", "last_synced_at": "2026-09-26T07:03:45.069Z", "location_count": 2, "location_summary": "Santa Barbara, California • Honolulu, Hawaii", "locations": [ { "city": "Santa Barbara", "state": "California" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT03668808" }, { "nct_id": "NCT03874715", "title": "Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "Insulin Aspart SAR341402", "type": "DRUG" }, { "name": "Insulin Aspart", "type": "DRUG" }, { "name": "Insulin glargine U100", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 210, "start_date": "2019-03-11", "completion_date": "2020-07-08", "has_results": true, "last_update_posted_date": "2024-04-17", "last_synced_at": "2026-09-26T07:03:45.069Z", "location_count": 33, "location_summary": "Concord, California • Temecula, California • Ventura, California + 30 more", "locations": [ { "city": "Concord", "state": "California" }, { "city": "Temecula", "state": "California" }, { "city": "Ventura", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Waterbury", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03874715" }, { "nct_id": "NCT05462756", "title": "A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes", "Type 2 Diabetes Treated With Insulin" ], "interventions": [ { "name": "Insulin Efsitora Alfa", "type": "DRUG" }, { "name": "Insulin Lispro (U100)", "type": "DRUG" }, { "name": "Insulin Glargine (U100)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 730, "start_date": "2022-08-11", "completion_date": "2024-02-27", "has_results": true, "last_update_posted_date": "2025-04-27", "last_synced_at": "2026-09-26T07:03:45.069Z", "location_count": 24, "location_summary": "Hamden, Connecticut • Clearwater, Florida • Miami Lakes, Florida + 19 more", "locations": [ { "city": "Hamden", "state": "Connecticut" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Miami Lakes", "state": "Florida" }, { "city": "Weston", "state": "Florida" }, { "city": "Blackfoot", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT05462756" }, { "nct_id": "NCT01499095", "title": "Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Lantus (Insulin glargine)", "type": "DRUG" }, { "name": "HOE901-U300 (new formulation of insulin glargine)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 811, "start_date": "2011-12", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2022-03-23", "last_synced_at": "2026-09-26T07:03:45.069Z", "location_count": 110, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 90 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01499095" }, { "nct_id": "NCT05514535", "title": "A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2", "Obesity" ], "interventions": [ { "name": "Semaglutide", "type": "DRUG" }, { "name": "Insuline glargine U100 (reduced)", "type": "DRUG" }, { "name": "Insuline glargine U100 (titrated)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 573, "start_date": "2022-08-29", "completion_date": "2025-04-09", "has_results": true, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-09-26T07:03:45.069Z", "location_count": 145, "location_summary": "Sheffield, Alabama • Glendale, Arizona • Mesa, Arizona + 113 more", "locations": [ { "city": "Sheffield", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Searcy", "state": "Arkansas" }, { "city": "Searcy", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05514535" } ] }